1 / 2

Years of Follow-up

Time to Primary Outcome. # at Risk. Yr 1. Yr 2. Yr 3. Yr 4. Yr 4.5. T. 8,542. 8,177. 7,778. 7,420. 7,051. 4,575. R. 8,576. 8,214. 7,832. 7,472. 7,093. 4,562. 0.25. 0.20. 0.15. Telmisartan. Cumulative Hazard Rates. Ramipril. 0.10. 0.05.

erna
Télécharger la présentation

Years of Follow-up

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Time to Primary Outcome # at Risk Yr 1 Yr 2 Yr 3 Yr 4 Yr 4.5 T 8,542 8,177 7,778 7,420 7,051 4,575 R 8,576 8,214 7,832 7,472 7,093 4,562 0.25 0.20 0.15 Telmisartan Cumulative Hazard Rates Ramipril 0.10 0.05 1,412 (16.5%) vs. 1,423 (16.7%); RR 1.01 (0.94-1.09) 0.0 0 1 2 3 4 Years of Follow-up Adapted from The ONTARGET Investigators. N Engl J Med 2008;358:1547-59.

  2. Adherence Rates of Antihypertensive Medication During Six to 24 Months in Saskatchewan 80 ** 6 mos * * * 12 mos 70 18 mos 60 24 mos 50 40 Percentage (%) 30 20 BB 10 0 bb DIUR ACEI CCB OTHER COMBO ARB *P=0.001 vs. each of the other classes; **P=0.030 vs. DIUR, P=0.002 vs. others Adapted from Chaput AJ. Saskatchewan Health Database

More Related